You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Reversal of Myocardial Infarction by Localized Stimulation

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: 102

    DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Fast Spectral Imaging Device For Tumor Margin Mapping

    SBC: Zenalux Biomedical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The American Cancer Society estimates that a total of 240,430 new breast cancers were diagnosed in 2007 (178,400 new cases of invasive breast cancer, and 62,030 new cases of in situ breast cancer). Approximately 180,000 of these patients undergo breast conserving surgery (BCS), also called lumpectomy. Multiple recent studies show that a staggering 20-70% of the ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes

    SBC: VASCULAR PHARMACEUTICALS            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objective of the proposed studies is to develop a monoclonal antibody that can be administered safely to patients with diabetes that will inhibit atherosclerosis. Insulin-like growth factor-I has been implicated in the initiation of the proliferative phase of atherosclerotic lesion development but inhibiting IGF-I receptor activity may lead to tox ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Drug for Septicemia Targets A1 ARs

    SBC: ENDACEA, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Despite the availability of newer antimicrobial agents, improved supportive care, and the introduction of an FDA approved adjunctive therapy for sepsis, (Xigris(r), drotrecogin alfa), the mortality rate for severe sepsis and septic shock of 30-60% remains high. Endacea, Inc. (Research Triangle Park, NC) approaches sepsis with a proprietary diagnostic/biomarker ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Restoration of Skin Structure and Function Post-Wounding

    SBC: FirstString Research, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The wound repair process in skin is initiated immediately after an injury and induces a cascade of events including inflammation, proliferation, and scar differentiation. The adverse changes in skin structure and function resulting from scar tissue affects over 35 million US citizens a year resulting in costs of more than 7 billion dollars). The founders of Fir ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Therapy for Staphylococcal Enterotoxin B Poisoning

    SBC: SOYMEDS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a significant human pathogen which can produce a variety of toxins, including the exotoxin, staphylococcal enterotoxin B (SEB). SEB is highly toxic in small doses, and the compact structure of this protein makes it resistant to heat and denaturation. The combination of toxicity and stability caused this toxin to be selected for weaponiz ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government